Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05310643 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Study acronym: NIPIRESCUE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 1, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 15, 2024 to Sep 2025v4 Show 6 more changesShow less
    • Study sites: 6 to 9
    • Study completion date: Sep 30, 2027 to Sep 2027
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: 9 to 5
    • Study description expanded, about 95 words
    • Study title shortened, about 9 words
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 15, 2022 to May 5, 2022
    • Site details revised at 6 of 6 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.
Trial Details
NCT Number NCT05310643
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov